Voyager Therapeutics Inc (VYGR) Stock Analysis

Voyager Therapeutics Inc (VYGR) is a publicly traded company in the HEALTHCARE sector. It trades at $3.59, carries a market capitalization of $229.00M. This page summarizes the public market data, fundamentals, and frequently asked questions for VYGR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Voyager Therapeutics Inc currently has a Bullish sentiment score of 0.51.

About Voyager Therapeutics Inc

Voyager Therapeutics Inc. (VYGR) is a pioneering clinical-stage gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for severe neurological disorders. By leveraging its proprietary adeno-associated virus (AAV) platform, Voyager focuses on delivering targeted and sustained gene therapies that have the potential to transform patient outcomes in chronic neurological conditions. The company boasts a promising pipeline of investigational...

GNG Research Analysis

GNG Research scores Voyager Therapeutics Inc (VYGR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VYGR.

Frequently Asked Questions

Does VYGR pay dividends?

Voyager Therapeutics Inc (VYGR) does not currently pay a regular dividend.

What is VYGR's market cap?

Voyager Therapeutics Inc (VYGR) has a market capitalization of $229.00M with a current stock price of $3.59.